We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

NTBL Notable Labs Ltd

-0.0799 (-2.11%)
Dec 01 2023 - Closed
Delayed by 15 minutes


Draw Mode:

Volume 61,290
Bid Price 3.43
Ask Price 4.10
News -
Day High 3.8861


52 Week Range


Day Low 3.36
Company Name Stock Ticker Symbol Market Type
Notable Labs Ltd NTBL NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.0799 -2.11% 3.71 20:00:00
Open Price Low Price High Price Close Price Prev Close
3.80 3.36 3.8861 3.71 3.7899
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
459 61,290 $ 3.69 $ 226,341 - 2.25 - 5.27
Last Trade Time Type Quantity Stock Price Currency
19:56:01 2 $ 3.43 USD

Notable Labs Ltd Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
33.39M 9.00M - 658k -32.3M -3.59 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Notable Labs News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No NTBL Message Board. Create One! See More Posts on NTBL Message Board See More Message Board Posts

Historical NTBL Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.724.243.363.9232,801-0.01-0.27%
1 Month2.694.242.653.4928,6551.0237.92%
3 Months4.505.272.253.7457,628-0.79-17.56%
6 Months4.505.272.253.7457,628-0.79-17.56%
1 Year4.505.272.253.7457,628-0.79-17.56%
3 Years4.505.272.253.7457,628-0.79-17.56%
5 Years4.505.272.253.7457,628-0.79-17.56%

Notable Labs Description

Vascular Biogenics Ltd is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of first-in-class treatments for cancer. The lead product candidate of the company is VB-111 which is a gene-based biologic which is being developed for solid tumor indications for recurrent glioblastoma, an aggressive form of brain cancer. The company is also engaged in conducting a program targeting anti-inflammatory diseases, based on the use of Lecinoxoid platform technology. The product brands of the company include VTS, Vascular Targeting Systems, Vbl, Vascular Biogenics And Vascular Therapeutics.

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 |